Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Immunotherapy for CD19 Positive Lymphoma
NCT03086954Phase 1Unknown
- Sponsor
- Sinobioway Group Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Mar 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous anti-CD19 CAR-T cells in B cell lymphoma, sponsored by Sinobioway Group Co., Ltd. Primary endpoint: Objective Reaction Rate at 90 days. Status: unknown.
02
Drugs
autologous anti-CD19 CAR-T cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03086954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086954.